Expression and significance of c-myc and CD24 in colorectal cancer

Abstract

Abstract:【Abstract】ObjectiveTo determine the expression of cmyc and CD24 in colorectal carcinoma, colorectal polyp and normal mucosa, and to explore the role and correlation of them in the carcinogenesis of colorectal carcinoma. MethodsThe expression of cmyc and CD24 in colorectal carcinoma (n=60), colorectal adenomatous polyp (n=45), colorectal hyperplastic polyp (n=15) and the adjacent noncancerous tissue (n=30) was observed by immunohistochemical assay. ResultsThe positive rate of cmyc in colorectal carcinoma were 73.3%, significantly higher than that in colorectal adenomatous polyp 44.4% (χ2=9.016 8, P＜0.01), colorectal hyperplastic polyp 13.3% (χ2=18.215 9, P＜0.01) and adjacent noncancerous tissue 6.7% (χ2=25.133 0, P＜0.01); the positive rate of CD24 in colorectal carcinoma was 76.7%, significantly higher than that in colorectal hyperplastic polyp 6.7% (χ2=25.133 0, P＜0.01) and adjacent noncancerous tissue 3.3% (χ2=43.107 4, P＜0.01). cmyc expression in colon cancer was significantly correlated with cancer site (χ2=8.352 3, P＜0.01), lymph node metastasis (χ2=4.275 1, P＜0.05), differentiation (χ2=4.115 3, P＜0.05) and TNM stage (χ2=5.739 9, P＜0.05). CD24 expression in colon cancer was significantly correlated with cancer size (χ2=9.333 6, P＜0.01), lymph node metastasis (χ2=7.693 0, P＜0.01), differentiation (χ2=5.870 0, P＜0.05) and TNM stage (χ2=4.498 7, P＜0.05). There was a positive correlation relationship between CD24 and cmyc in colorectal carcinoma tissue (χ2=10.824 9, r=0.39, P＜0.05).ConclusionThe expression of cmyc and CD24 are high in colorectal cancer, having a significant correlation with some of the clinicaopathological features. cmyc is likely to act as a downstream target gene of CD24 signaling pathway, whose expression is probably regulated by CD24 in colorectal carcinoma tissue.

Key words:Colorectal neoplasms,Immunohistochemistry,Genes, myc,CD24

CHEN Wen-Jun, DONG Chong-Hai, TIAN Zi-Bin. Expression and significance of c-myc and CD24 in colorectal cancer[J]. Journal of International Oncology, 2015, 42(4): 255-258.

References

［1］ Holt SE, Shay JW. Role of telomerase in cellular proliferation and cancer［J］. J Cell Physiol, 1999, 180(1): 1018. ［2］ Sagawa Y, Nishi H, Isaka K, et a1. The correlation of TERT expression with cmyc expression in cervical cancer［J］. Cancer Lett, 2001, 168(1): 4550. ［3］王伟飞, 王新颖, 岳辉, 等. CD24在大肠癌组织中的表达及其对癌细胞增殖的影响［J］. 实用癌症杂志, 2011, 26(1): 3741. ［4］ Tollefshol TO, Andrews LG. Mechanisms for telomerase gene control in aging cells and tumorigenesis［J］. Med Hypotheses, 2001, 56(6): 630637. ［5］ Baudino TA, McKay C, PendevilleSamain H, et al. cmyc is essential for vasculogenesis and angiogenesis during development and tumor progression［J］. Genes Dev, 2002, 16(19): 25302533. ［6］ Smith SC, Oxford G, Wu Z, et al. The metastasisassociated gene CD24 is regulated by Ral GTPase and is a mediator of cell proliferation and survival in human cancer［J］. Cancer Res, 2006, 66(4): 19171922. ［7］ Aigner S, Sthoeger ZM, Fogel M, et al. CD24, a mucintype glycoprotein is a ligand for Pselection on human tumor cells［J］. Blood, 1997, 89(9): 33853395. ［8］刘剑仑, 葛莲英, 张贵年. p53、cmyc、PCNA在大肠癌过度表达的临床意义［J］. 大肠肛门病外科杂志, 2004, 10(1): 2123. ［9］ Sagiv E, Memeo L, Karin A, et al. CD24 is a new oncogene, early at the multistep process of colorectal cancer carcinogenesis［J］.Gastroenteroloty, 2006, 131(2): 630639. ［10］李超, 许芝林, 赵峥, 等. Kras基因与cmyc基因在大肠癌中的表达及相关性研究［J］. 哈尔滨医科大学学报, 2009, 43(6): 572575. ［11］ Weichert W, Denkert C, Burkhardt M, et al. Cytoplasmic CD24 expression in colorectal cancer independently correlates with shortened patient survival［J］. Clin Cancer Res, 2005, 11(18): 65746581. ［12］ He TC, Sparks AB, Rago C, et al. Identifition of cmyc as target of the APC pathway［J］. Science, 1998, 281(5382): 15091512.

[1]	Zhang Rui, Chu Yanliu.Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota[J]. Journal of International Oncology, 2024, 51(6): 370-375.
[2]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[3]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao.Effect of cancer nodules on liver metastases after radical resection of colorectal cancer[J]. Journal of International Oncology, 2024, 51(5): 280-285.
[4]	Sun Guobao, Yang Qian, Zhuang Qingchun, Gao Binbin, Sun Xiaogang, Song Wei, Sha Dan.Research progress on the histopathological growth patterns of colorectal liver metastasis[J]. Journal of International Oncology, 2024, 51(2): 114-118.
[5]	Liu Debao, Sun Ziwen, Lu Shoutang, Xu Haidong.Expression and clinical significance of ASB6 in colorectal cancer tissues[J]. Journal of International Oncology, 2023, 50(8): 470-474.
[6]	Chen Zhuo, Tao Jun, Chen Lin, Ke Jing.Value of detection of peripheral blood miR-194 combined with fecal miR-143 in the clinical screening of colorectal cancer[J]. Journal of International Oncology, 2023, 50(5): 268-273.
[7]	Huang Zhen, Zhang Caiyutian, Ke Shaobo, Shi Wei, Zhao Wensi, Chen Yongshun.Construction of postoperative prognosis model for patients with colorectal cancer[J]. Journal of International Oncology, 2023, 50(3): 157-163.
[8]	Xu Liangfu, Li Yuanfei.Research progress on tumor microenvironment and immune combination therapy of MSS colorectal cancer[J]. Journal of International Oncology, 2023, 50(3): 186-190.
[9]	Liao Lihua, Wang Shaohong, Chen Hongcai, Zhao Yongqiang.Value of cell paraffin block immunohistochemistry and pleural effusion CRKL and MIC-1 in the diagnosis of malignant pleural effusion[J]. Journal of International Oncology, 2023, 50(2): 71-75.
[10]	Liu Yujie, Zhao Zhiqiang, Wang Zicheng.Levels and diagnostic value of TOP2A and ERBB2 in peripheral blood mononuclear cells of patients with early colorectal cancer[J]. Journal of International Oncology, 2023, 50(12): 717-722.
[11]	Tao Hong, Yin Hong, Luo Hong, Tao Jiayu.Potential strategies for targeting tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors for colorectal cancer[J]. Journal of International Oncology, 2023, 50(11): 683-687.
[12]	Wang Xi, Wu Chuanqing.Research progress in reversing multidrug resistance in colorectal cancer[J]. Journal of International Oncology, 2023, 50(1): 42-46.
[13]	Gao Yizhao, Liu Yang, Liu Qiulong, Xing Jinliang.Application of circulating cell-free nucleic acid in clinical diagnosis and treatment of colorectal cancer[J]. Journal of International Oncology, 2022, 49(9): 555-559.
[14]	He Zhefeng, Wu Yiyang, Li Zhenjun, Ying Xiaojiang.Predictive value of inflammatory markers in colorectal cancer[J]. Journal of International Oncology, 2022, 49(9): 560-563.
[15]	Zhao Ying, Zhang Gehong.Study on the correlations between AGR, PLR and NLR changes and chemotherapy efficacy of metastatic colorectal cancer[J]. Journal of International Oncology, 2022, 49(8): 473-477.